Document is current

Article History

Received: 5 July 2023

Accepted: 19 July 2023

First Online: 31 July 2023

Declarations

:

: The study protocol was approved by the Certified Review Board of Fukushima Medical University (no. F2023001). The study is now conducted in accordance with the Declaration of Helsinki and the Clinical Trial Act in Japan. After the patients are initially screened for eligibility based on their prior medical records, they will receive adequate explanations about the trial plan before they provide a written informed consent.

: Not applicable.

: AT received honoraria from Boehringer Ingelheim and research funding from GlaxoSmithKline, Takeda, Bristol-Myers Squibb and Novo Nordisk. HS has received speaking fees from Bayer, Daiichi Sankyo, AstraZeneca, and Novartis Pharma and scholarship from Bayer and Chugai Pharmaceutical. TI received lecture fees from JCR Pharmaceuticals and Kyowa Kirin. HY reported receiving lecture fee from Kyowa Kirin. MMiyazono has received honoraria from Chugai Pharmaceutical, Astellas, Kyowa Kirin, Mitsubishi Tanabe, Mochida Pharmaceutical, AstraZeneca, Bayer Yakuhin, Torii Pharmaceutical, Fuso Pharmaceutical Industries, Teijin Pharma, and Kissei Pharmaceutical, research grant from Chugai Pharmaceutical, and scholarship from Kyowa Kirin, Torii Pharmaceutical, Fuso Pharmaceutical Industries, and Kissei Pharmaceutical. NT received honoraria from Daiichi Sankyo, Novartis Pharma, Boehringer Ingelheim, Toa Eiyo, Bristol Myers Squibb, Pfizer, AstraZeneca, and Bayer Yakuhin. DF has received honoraria from Bayer Yakuhin, Daiichi Sankyo, and Otsuka Pharmaceutical. HT received research grants from AstraZeneca, Daiichi Sankyo, Janssen, Novo Nordisk, and Eli Lilly. KK received honoraria from AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim, Otsuka Pharmaceutical, and Novartis Pharma. MMoroi has received honoraria from Takeda, Sanofi, Bayer, Otsuka Pharmaceutical, Mitsubishi Tanabe, and Amicus Therapeutics and research grant from Teijin Pharma, Sanofi, Nihon Medi-physics, and Amicus Therapeutics. ST received honoraria from Otsuka Pharmaceutical, Ono Pharmaceutical, Daiichi Sankyo, Bayer Yakuhin, AstraZeneca, and Novartis Pharma. MS has received speaker's honoraria from Bayer Yakuhin. KT has received honoraria from Abbott Medical, Boston Scientific, Orbusneich, Kaneka, Japan Lifeline, Edwards Lifesciences, HeatFlow, Bayer Yakuhin, Medis, and Daiichi Sankyo. MN has received lecture fees from Kyowa Kirin, Astellas, GlaxoSmithKline, Daiichi Sankyo, Mitsubishi Tanabe, Chugai Pharmaceutical, Torii Pharmaceutical, JT, Alexion, Akebia, MSD, and Boehringer Ingelheim and research support from JT, Kyowa Kirin, Astellas, Ono Pharmaceutical, Takeda, Daiichi Sankyo, Mitsubishi Tanabe, Chugai Pharmaceutical, Torii Pharmaceutical, Kissei Pharmaceutical, and Boehringer Ingelheim. KN has received honoraria from AstraZeneca, Bayer Yakuhin, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly Japan, Kowa, Mitsubishi Tanabe, MSD, Novartis Pharma, Novo Nordisk, Ono Pharmaceutical, Otsuka Pharmaceutical, and Takeda, research grant from Asahi Kasei, Astellas, Boehringer Ingelheim, Fuji Yakuhin, Mitsubishi Tanabe, Mochida Pharmaceutical, Novartis Pharma, and Teijin Pharma, and Scholarship from Bayer Yakuhin, Medtronic, Teijin Pharma. AT and KN are Editorial Board members of the journal, and they were not involved in handling this manuscript during the submission and the review processes. Other authors declare no potential conflict of interest.